Keytruda's Strongest Approvals by Cancer Type
Keytruda (pembrolizumab), a PD-1 inhibitor from Merck, shows highest efficacy in cancers with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMRR), regardless of tumor location. The FDA granted a tumor-agnostic approval for these in 2017, based on trials like KEYNOTE-158 where objective response rates reached 40% in MSI-H/dMMR solid tumors.[1][2] It also excels in:
- Melanoma: First approval in 2014; 5-year survival rates over 40% in advanced cases when combined with other therapies, per KEYNOTE-006.[1]
- Non-small cell lung cancer (NSCLC): Over 20% of approvals; frontline use in PD-L1-high tumors yields median survival of 30 months vs. 14 months for chemo.[1][3]
- Head and neck squamous cell carcinoma: Improves survival by 5 months in recurrent cases.[1]
How Keytruda Works Best in These Cancers
It blocks PD-1 to unleash T-cell attacks on tumors, succeeding most in immunogenic cancers with high tumor mutational burden (TMB-H) or PD-L1 expression. MSI-H cancers fit this profile due to DNA repair defects creating neoantigens.[2] Response rates drop in low-expression tumors, explaining weaker performance elsewhere.
Cancers Where It Underperforms or Lacks Strong Data
Limited success in pancreatic, prostate, or glioblastoma cancers, where trials like KEYNOTE-028 showed <10% response rates.[1] Not recommended as monotherapy there; combos are experimental.
Comparison to Competitors Like Opdivo
Keytruda edges Opdivo (nivolumab) in NSCLC (PD-L1 ≥50%: 25% vs. 19% response) but trails in Hodgkin lymphoma.[3] Both shine in MSI-H, but Keytruda has broader tumor-agnostic use.
Ongoing Trials and Future Expansions
Phase 3 trials target triple-negative breast cancer (KEYNOTE-522: pathology complete response 65%) and renal cell carcinoma combos.[1] Pediatric approvals cover MSI-H tumors.[2]
Patient Survival Stats in Top Indications
| Cancer | 5-Year OS Rate (Advanced) | Key Trial |
|--------|---------------------------|-----------|
| Melanoma | 34-52% | KEYNOTE-006 [1] |
| MSI-H/dMMR | 48% | KEYNOTE-158 [2] |
| NSCLC (PD-L1 high) | 29% | KEYNOTE-024 [3] |
[1]: FDA Keytruda Label
[2]: NEJM KEYNOTE-158
[3]: Merck Keytruda Data